Methodology for the metric restoration of the historical cartography applied to Francisco Coello's cartografic series of the Royal Site of Aranjuez

Hojas Kilométricas (Kilometric Sheets). Specifically, the study focuses on those sheets referring to the city centre and surrounding area of the Royal Site of Aranjuez, a town in the south of the Province of Madrid. The aim of this study is to restore the actual size and measurements of scanned images of the Hojas Kilométricas. This would allow us, among other things, to reestablish both the format and scale of the original plans. To achieve this goal it is necessary to rectify and then georeference these images, i.e. assign them a geographic reference system. This procedure is essential in the overlaying and comparison of the Hojas Kilométricas of the Royal Site with other historical cartography as well as other sources related to the same area from different time periods. Subsequent research would allow us, for example, to reconstruct the time-evolution of the urban area, to spot new construction and to pinpoint the locations of any altered or missing buildings or architectural features. In addition, this would allow us to develop and integrate databases for GIS models applicable to the management of our cultural heritage

El color en la cartografía histórica

El uso del color en la cartografía histórica no es un simple recurso estético para ilustrar planos, mapas y cartas. Fundamentalmente es un convencionalismo gráfico para representar la realidad de manera convincente. También, en algunas ocasiones, el color adquiere, incluso, un valor simbólico. En esta comunicación trataremos de analizar el uso del color en la cartografía histórica, desde el signo y desde el significado, es decir, desde la materialización del pigmento que colorea un fragmento del plano según una codificación determinada, hasta la percepción que transmite el color y la tonalidad del elemento representado. Hacemos mención de los materiales que forman un color, de las técnicas de iluminación y lavado de planos y de la progresiva normalización de los diversos criterios en su uso

Agreement in the assessment of metastatic spine disease using scoring systems

Licensed under the Creative Commons Attribution-Non Commercial-No Derivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0

Awake prone positioning does not reduce the risk of intubation in COVID-19 treated with high-flow nasal oxygen therapy: a multicenter, adjusted cohort study

Abstract Background Awake prone positioning (awake-PP) in non-intubated coronavirus disease 2019 (COVID-19) patients could avoid endotracheal intubation, reduce the use of critical care resources, and improve survival. We aimed to examine whether the combination of high-flow nasal oxygen therapy (HFNO) with awake-PP prevents the need for intubation when compared to HFNO alone. Methods Prospective, multicenter, adjusted observational cohort study in consecutive COVID-19 patients with acute respiratory failure (ARF) receiving respiratory support with HFNO from 12 March to 9 June 2020. Patients were classified as HFNO with or without awake-PP. Logistic models were fitted to predict treatment at baseline using the following variables: age, sex, obesity, non-respiratory Sequential Organ Failure Assessment score, APACHE-II, C-reactive protein, days from symptoms onset to HFNO initiation, respiratory rate, and peripheral oxyhemoglobin saturation. We compared data on demographics, vital signs, laboratory markers, need for invasive mechanical ventilation, days to intubation, ICU length of stay, and ICU mortality between HFNO patients with and without awake-PP. Results A total of 1076 patients with COVID-19 ARF were admitted, of which 199 patients received HFNO and were analyzed. Fifty-five (27.6%) were pronated during HFNO; 60 (41%) and 22 (40%) patients from the HFNO and HFNO + awake-PP groups were intubated. The use of awake-PP as an adjunctive therapy to HFNO did not reduce the risk of intubation [RR 0.87 (95% CI 0.53–1.43), p = 0.60]. Patients treated with HFNO + awake-PP showed a trend for delay in intubation compared to HFNO alone [median 1 (interquartile range, IQR 1.0–2.5) vs 2 IQR 1.0–3.0] days (p = 0.055), but awake-PP did not affect 28-day mortality [RR 1.04 (95% CI 0.40–2.72), p = 0.92]. Conclusion In patients with COVID-19 ARF treated with HFNO, the use of awake-PP did not reduce the need for intubation or affect mortality. </jats:sec

Benchmarking empirical severity for the Yale-Brown Obsessive Compulsive Scale-Second Edition

The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) is considered the primary instrument for assessing the presence and severity of obsessive-compulsive disorder (OCD). Conceptual and empirical critiques inspired the development of an updated version of the instrument, the Yale-Brown Obsessive Compulsive Scale-Second Edition (Y-BOCS-II), with a higher ceiling of OCD severity to better differentiate between severe and the most debilitating OCD presentations, among other revisions. The Y-BOCS-II has demonstrated sound psychometric properties across diverse samples. Empirically derived severity benchmarks have been proposed for the original Y-BOCS, yielding somewhat different ranges than what has been commonly used in clinical and research settings, yet severity benchmarks for the Y-BOCS-II have yet to be established. Using a diverse, pooled sample of 2982 children and adults with OCD or obsessive-compulsive and related concerns across 13 countries, receiver-operating characteristic (ROC) analyses yielded severity benchmarks that largely mirrored the original Y-BOCS at the lower range of scores and extended the previously established benchmarks at the higher range of scores, owing to the increased ceiling of the instrument. The optimal benchmark ranges were determined as: non−/sub-clinical (0–14), mild (15–21), moderate (22–34), severe (35–50). Similar benchmarks were present across sex and age groups, and their accuracy was adequate in both a holdout sample and an independent sample of OCD patients from China (n = 78). Limitations and implications for the use of the Y-BOCS-II in clinical and research settings are discussed. •This study sought to establish severity benchmarks for the Y-BOCS-II.•Benchmarks largely mirrored the Y-BOCS benchmarks at the lower range of scores.•Benchmarks were sub-clinical (0–14), mild (15–21), moderate (22–34), and severe (35–50).•Similar benchmarks were suggested across sex and age groups.•Findings were affirmed in a holdout sample from China